Doctors and scientists at MSK have led the development of many of the drugs used to treat chronic myeloid leukemia. The first targeted therapy ever approved for CML, imatinib (Gleevec ®), was ...

Explore the evolving treatment landscape of chronic myeloid leukemia with asciminib, a promising new TKI showing high ...

The investigators examined the records of 2857 patients with Ph+ CML diagnosed from 2000 to 2019. Their median age fell between 55 and 59 years of age, with 57% younger than age 60, 20% between ...

Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places.

Navtemadlin (KRT-232) is a novel, potent, and selective oral MDM2 inhibitor. Currently, the drug is undergoing an Open-Label, ...

In Patients with CML, Frailty—Not Age—Is a Strong Predictor of Poor Outcomes —Investigators examined the impact of frailty on hospital outcomes in patients with chronic myeloid leukemia ...

Drs Michael J. Mauro and Michael W. Deininger discuss the evolution of chronic myeloid leukemia, better access to treatment, improved global cure rates, and a clearer definition of the word cure.

Drs Michael J. Mauro and Jerald P. Radich discuss monitoring and diagnostics in chronic myeloid leukemia, including the Philadelphia chromosome and how it plays into the current treatment of CML.